NEWS

Research Program

11th Annual ATS Foundation Research Program Benefit

With an assortment of hors d’oeuvres and live music the ATS Foundation kicked off its 11th Annual Research Program Benefit on Saturday, May 18, 2019. More than 700 attendees gathered at Union Station to recognize Sharon Rounds, MD, as the recipient of the 2019 Breathing for Life Award, as well as honor grant awardees, celebrate the ATS Foundation Research Program’s successes, and connect with friends.

The Breathing for Life Award is given by the ATS Foundation to recognize philanthropy and scientific accomplishments. As ATS president, Dr. Rounds championed the formation of the ATS Foundation in 2004. Since then, the Foundation has given donors the confidence that one hundred percent of all donations for research support the ATS Foundation Research Program. In addition to being one of the most generous supporters of the Foundation, she served on the Foundation’s board from 2012 until 2018.

The gala raised more than $654,000 from corporate, medical institution, and individual supporters with proceeds supporting research grants for young investigators.

In 2019, the ATS Foundation will fund more than 30 awards, including unrestricted research awards in pulmonary, critical care, and sleep medicine; research partner awards; and awards for outstanding alumni from the Methods in Epidemiologic, Clinical, and Operations Research (MECOR) program. Since 2004, the ATS Foundation Research Program has provided $19.3 million in grants to more than 263 investigators, who have gone on to secure $330 million in federal funding.

VIDEO: Dr. Sharon Rounds, MD, 2019 Breathing for Life Awardee


The ATS Foundation thanks Genentech and GSK for their support at the Sapphire Level for the 11th Annual ATS Foundation Research Program Benefit; Mylan Inc., and Theravance Biopharma at the Crystal Level; Sanofi Genzyme-Regeneron, Mallinckrodt Pharmaceuticals And Novartis at the Gold Level; Sunovion Pharmaceuticals, Inc, Freeman, Gilead Sciences, Inc., Vertex, Boehringer Ingelheim, Insmed and AstraZeneca at the Silver Level; Ascend Integrated Media, NBRC and Sunovion Pharmaceuticals, Inc at the Bronze Level.


The ATS Foundation also thanks the many individuals and medical institutions that have stepped forward to support the Research Program and young investigators in pulmonary, critical care, and sleep medicine.